首页 › 基金 › RA CAPITAL MANAGEMENT, L.P. › VOR
RA CAPITAL MANAGEMENT, L.P. 对 VOR 的持仓历史
VOR BIOPHARMA INC · 医疗保健
RA CAPITAL MANAGEMENT, L.P. 在 Q3 2026 的 13F 申报中披露持有 VOR(VOR BIOPHARMA INC)4,503,882 股,市值约 US$85.9M,约占其申报组合的 0.88%,在其申报持仓中市值排名第 24 位。 RA CAPITAL MANAGEMENT, L.P. 最近 13 个申报季度中有 13 个季度披露了 VOR 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
RA CAPITAL MANAGEMENT, L.P. 对 VOR 的持仓演变
RA CAPITAL MANAGEMENT, L.P. 于 Q3 2023 首次披露 VOR 持仓:22,748,880 股(约 US$48.2M)。 该持仓在 Q3 2025 达到峰值 1,982,301 股,市值约 US$96.6M。 在 13 次申报中,RA CAPITAL MANAGEMENT, L.P. 3 次增持、2 次减持、7 次保持不变。 最近一期申报(Q3 2026)显示持股 4,503,882 股、市值约 US$85.9M,环比增持 2,101,787 股。。 持仓曾出现大幅变动:Q3 2025 减持约 95% (随后一个季度股价下跌 73%)、Q4 2025 增持约 173% (随后一个季度股价上涨 36%)、Q3 2026 增持约 87% (随后一个季度股价基本持平)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 22.75M | $48.23M | 新进 |
| Q4 2023 | 22.75M | $51.18M | 持有 |
| Q1 2024 | 22.75M | $53.91M | 持有 |
| Q2 2024 | 22.75M | $22.75M | 持有 |
| Q3 2024 | 22.75M | $15.92M | 持有 |
| Q4 2024 | 39.65M | $44.01M | 增持 |
| Q1 2025 | 39.65M | $28.45M | 持有 |
| Q2 2025 | 39.65M | $64.23M | 持有 |
| Q3 2025 | 1.98M | $96.58M | 减持 |
| Q4 2025 | 5.40M | $70.70M | 增持 |
| Q1 2026 | 5.40M | $96.43M | 持有 |
| Q2 2026 | 2.40M | $44.22M | 减持 |
| Q3 2026 | 4.50M | $85.93M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 VOR 与 13F 数据
VOR(VOR BIOPHARMA INC)属于医疗保健行业。我们追踪的基金中还有 70 只申报持有 VOR,申报仓位最大的包括:TCG Crossover Management, LLC (US$108.2M), FCPM III SERVICES B.V. (US$65.0M), Venrock Adviser, LLC (US$58.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 VOR 的基金
- TCG Crossover Management, LLC 5.67M 股 · $108.24M · Q3 2026
- FCPM III SERVICES B.V. 3.41M 股 · $64.97M · Q3 2026
- Venrock Adviser, LLC 3.04M 股 · $58.04M · Q3 2026
- Frazier Life Sciences Management, L.P. 2.74M 股 · $52.35M · Q3 2026
- Caligan Partners LP 1.93M 股 · $36.73M · Q3 2026
- GREAT POINT PARTNERS LLC 1.13M 股 · $21.50M · Q3 2026
- Nantahala Capital Management, LLC 931.64K 股 · $17.78M · Q3 2026
- Paradigm Biocapital Advisors LP 889.58K 股 · $16.97M · Q3 2026
- NAN FUNG TRINITY (HK) Ltd 721.55K 股 · $13.77M · Q3 2026
- NEXTBio Capital Management LP 620.93K 股 · $11.85M · Q3 2026
- Rosalind Advisors, Inc. 609.20K 股 · $11.62M · Q3 2026
- Vivo Capital, LLC 550.36K 股 · $10.50M · Q3 2026
更多关于 RA CAPITAL MANAGEMENT, L.P.
常见问题
How long has RA CAPITAL MANAGEMENT, L.P. held VOR?
RA CAPITAL MANAGEMENT, L.P. has disclosed VOR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in VOR?
As of Q3 2026, RA CAPITAL MANAGEMENT, L.P. holds 4.50M shares of VOR (VOR BIOPHARMA INC), valued at $85.93M, representing 0.88% of its reported portfolio and ranking #24.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling VOR?
In the latest 13F filing (Q3 2026), RA CAPITAL MANAGEMENT, L.P. increased its position in VOR. The position peaked in Q3 2025 at 1.98M shares.
Which other funds hold VOR?
Other major institutional holders of VOR include TCG Crossover Management, LLC, FCPM III SERVICES B.V., Venrock Adviser, LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.